首页> 外文期刊>Cancer biology & therapy >EGFR expression variance in paired colorectal cancer primary and metastatic tumors.
【24h】

EGFR expression variance in paired colorectal cancer primary and metastatic tumors.

机译:结直肠癌配对的原发性和转移性肿瘤中的EGFR表达差异。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Previous studies indicate that drugs targeting the Epidermal Growth Factor Receptor (EGFR) signaling pathways can induce objective responses, prolong time to progression and improve survival of patients with metastatic colorectal cancer (mCRC). EGFR expression in the primary tumour may not predict response to these agents and data is conflicting regarding the correlation of EGFR expression in the primary tumour with the metastatic site. In other tumour sites, the presence of EGFR mutations was associated with efficacy in a subset of patients. OBJECTIVES: The goal of this study is to correlate tumour EGFR expression between primary and liver metastatic sites, and to assess the mutational status in the EGFR kinase domain. METHODS: This is a single center retrospective study of patients who underwent surgical resection of CRC, for whom paired paraffin-embedded tissue blocks of primary tumours and resected liver metastases were available. EGFR immunostaining and mutation analyses were preformed. RESULTS: Fifty six paired colorectal primaries and metastases were available for analysis. EGFR was detectable in 96.6% of the primary samples and in 89.7% of the metastatic samples. Perfect concordance in the intensity score between the primary and the metastases was found in 46.5% of the cases. While individual pairs were poorly concordant for intensity, the proportion of primaries with intense staining was similar to the proportion with intense staining in the metastatic samples. Overall survival did not correlate with either EGFR expression in the primary tumour, or with EGFR expression in the metastasis. There were 2 cases with mutations in the EGFR kinase domain. Both mutations were found in exon21 C>T. CONCLUSIONS: In this analysis, EGFR expression in the primary tumor site was not predictive of its level in the metastasis. EGFR expression levels in the primaries and in the metastases do not appear to be useful prognostic markers.
机译:背景:先前的研究表明,靶向表皮生长因子受体(EGFR)信号通路的药物可以诱导客观反应,延长进展时间并改善转移性结直肠癌(mCRC)患者的生存率。原发性肿瘤中的EGFR表达可能无法预测对这些药物的反应,有关原发性肿瘤中EGFR表达与转移部位的相关性数据矛盾。在其他肿瘤部位,EGFR突变的存在与部分患者的疗效相关。目的:本研究的目的是使原发性和肝转移位点之间的肿瘤EGFR表达相关,并评估EGFR激酶域中的突变状态。方法:这是一项单中心回顾性研究,对接受CRC手术切除的患者进行了研究,他们可获得成对的石蜡包埋的原发性肿瘤组织块和切除的肝转移瘤。进行了EGFR免疫染色和突变分析。结果:五十六对结直肠原发和转移可用于分析。在96.6%的主要样本和89.7%的转移样本中可检测到EGFR。在46.5%的病例中发现原发和转移之间的强度评分完全一致。虽然各对之间的强度不一致,但转移样品中带有强烈染色的原色比例与带有强烈染色的原色比例相似。总体生存率与原发肿瘤中的EGFR表达或转移中的EGFR表达均无关。有2例EGFR激酶结构域突变。两种突变均在外显子21 C> T中发现。结论:在该分析中,EGFR在原发肿瘤部位的表达不能预测其在转移中的水平。原发灶和转移灶中的EGFR表达水平似乎不是有用的预后标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号